DementiaNCT04226872
Supporting Family Caregivers of Persons Living With Dementia: Effectiveness and Sustainability of MT4C-In Care
A study testing My Tools for Care - In Care in people with Dementia and Family, run by University of Alberta at 4 sites in Canada.
Trial summary
When a person living with dementia moves into a long term care facility, their family members remain involved in their care. They learn new roles and make significant and often stressful adjustments. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- What is being tested?
- My Tools for Care - In Care
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 234 participants
- Where
- 4 sitesCanada
- Study dates
- 3 Feb 2020to 31 Oct 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Family caregivers (≥18 years of age) of a person ≥65 years of age who has dementia that lives in a long-term care home
- English-speaking
- Has a valid email address and access to a computer and internet.
Who cannot join
- Family caregivers of a person under the age of 65, who does not have dementia, or who does not reside in a long-term care home
- Care partner has died
- Non-English speaking
- Under 18 years of age
- No internet access or valid email
Trial locations and contacts
4 sites in 1 country.
Canada4 sites
University Of Alberta
Edmonton, Alberta, T6G 1C9
McMaster University
Hamilton, Ontario, L8S 4K1
University of Saskatchewan
Saskatoon, Saskatchewan, S7N 2Z4
University of Manitoba
Winnipeg, Manitoba, R3T 2N2
About this study
Official title: Supporting Family Caregivers of Persons Living With Dementia: Effectiveness and Sustainability of My Tools 4 Care-In Care
When a person living with dementia moves into a long term care facility, their family members remain involved in their care. They learn new roles and make significant and often stressful adjustments. These caregivers are an at-risk group, and evidence suggests that their mental health may actually worsen after the person they are caring for moves into long term care. The research team previously created a free, web-based, interactive, intervention called My Tools 4 Care-In Care (MT4C-In Care) and tested it with 37 caregivers in Alberta. Caregivers found the toolkit to be easy to use, feasible, acceptable, and satisfactory, and reported increased hope and decreased loss and grief, after using it. Additionally, they reported that the toolkit helped them through the transitions they experience when their family member lives in long term care.
In this next study we want to see if MT4C-In Care can improve the quality of life, hope, social support, self-efficacy, and decrease the loss, grief and loneliness of family caregivers. During phase 1 the existing MT4C-In Care toolkit was reviewed with input from family caregivers of persons living with dementia in long term care through focus group interviews. The toolkit is now being revised and will be tested, during phase 2, with 280 caregivers of persons living with dementia in long term care across 4 provinces in Canada (Alberta, Ontario, Saskatchewan, and Manitoba). These caregivers will be randomly assigned into an intervention (caregivers with access to MT4C-In Care) and a control group (no access to MT4C-In Care).
Read the detailed description
Background: Caregivers of Persons Living with Dementia (PLWD) in a Long Term Care (LTC) community are an at-risk group, and evidence suggests that the caregiver's mental health may actually worsen after the PLWD moves to LTC. Caregivers may report feelings of blame, self-doubt, loneliness, isolation, and powerlessness which negatively affect their mental health. This at-risk group requires support to maintain and improve their quality of life. My Tools 4 Care - In Care (MT4C-In Care) is a self-administered, multicomponent, flexible, and interactive website designed specifically to support family caregivers of PLWD in LTC to address this gap in service and the significant concerns about their mental health. The feasibility study in Alberta demonstrated that MT4C-In Care is informative, convenient, and easy to use; and shows potential to help caregivers cope with the transitions and adjustments beyond the PLWD's admission to LTC, increasing caregivers' hope and decreasing their loss and grief.
Purpose: The purpose of Phase 2 is to implement and evaluate MT4C-In Care to assess its effectiveness, and the influence of participant factors (i.e., gender, cultural background, age, etc.) on the use of MT4C-In Care across four Canadian provinces (Alberta, Saskatchewan, Manitoba, and Ontario). The ability of MT4C-In Care to improve hope, self-efficacy, quality of life, social support, and mental health, and decrease grief and loneliness will be rigorously assessed in a pragmatic effectiveness trial with a large sample. The rigorous pragmatic trial, with in-depth mixed methods, will demonstrate whether MT4C-In Care works across four Canadian provinces as well as the reasons and mechanisms underlying its effects. MT4C-In Care will be updated based on pragmatic trial results in Jan-Feb 2022.
Participants: Total of approximately 280 participants from four provinces will be recruited (100 each from Alberta and Ontario and 40 each from Saskatchewan and Manitoba). Each province will hire a recruitment specialist, and Alzheimer Societies and other community partners within each province will support recruitment of participants by including information in newsletters, distributing brochures, and/or attending support group meetings, etc. Recruited participants will be randomly assigned to the intervention and control group (140 participants each group) via a centralized web-based randomization service (REDCap).
Data Collection: Trained research assistants in each province will 1) track all participants' participation throughout the study, 2) conduct surveys with all participants by phone to assess whether or not the intervention was effective in improving outcomes over time, as compared to the control group, and 3) conduct in-depth telephone interview with five to fifteen participants (depending on the province; see below).
Number of Participants in Surveys and In-depth Interviews: Alberta and Ontario: surveys with all 100 participants and in-depth interviews with 15 participants; Saskatchewan and Manitoba: surveys with all 40 participants and in-depth interview with 5 participants.
Outcome Data Collection: Immediately before and after the intervention, outcome and process data will be collected from all caregivers.There will be 3 Data Collection Points: Baseline before the start of the intervention; 2-month follow up immediately post-intervention; 4 month follow up after the end of the intervention.
Data Analysis: Outcome will be analyzed (using Generalized Estimating Equations) to assess whether MT4C-In Care is effective in the intervention as compared to the control group over time. We anticipate that the intervention group will experience improved hope, mental health, quality of life, social support, and self-efficacy, and less loneliness and grief, as compared to the control group. 140 participants in each of the intervention and control groups will allow for rigorous testing of these hypotheses.
- Being tested
- My Tools for Care - In Care
- Keywords
- Caregivers, Quality of life, Dementia, Web-based intervention
- Medical subject headings
- Dementia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
My Tools for Care - In CareBehavioural
Self-administered web-based transition toolkit (My tools 4 Care - In Care) contains interactive activities and resources to help carers through transitions that they face after the person living with dementia has moved to a long-term care setting.
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | The intervention group will receive access to My Tools for Care - In Care for 2 months. They will also receive a copy of the Alzheimer Society's "The Progression Of Alzheimer's Disease - Overview Booklet". Receives: Behavioral: My Tools for Care - In Care |
| Control | No intervention | The control group will not receive the intervention (i.e. they will not access My Tools for Care - In Care). They will receive a copy of the Alzheimer Society's "The Progression Of Alzheimer's Disease - Overview Booklet". Data collection for outcome variables will be the same as participants in the intervention group. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in the 12-item Short-Form Health Survey (SF-12v2) - Mental Component Summary Score at two and four months
The SF-12v2 is a measure of health related quality of life and provides 2 scores 1) Mental Component Summary Score (MCS) and 2) Physical Component Summary Score (PCS). MCS scores range from 0 to 100, higher scores indicate better mental health related quality of life
Measured: Baseline, 2 months, 4 months
Secondary outcomes (6)
Change from baseline in the 12-item Short-Form Health Survey (SF-12v2) - Physical Component Summary Score at 2 and 4 months.
The SF-12v2 is a measure of health related quality of life and provides 2 scores 1) Mental Component Summary Score (MCS) and 2) Physical Component Summary Score (PCS). PCS scores range from 0 to 100, higher scores indicate better physical health related quality of life
Measured: Baseline, 2 months, 4 months
Change from baseline in the Herth Hope Index Score (HHI) at 2 and 4 months.
The HHI is a 12-item Likert-type scale used to measure hope. Items are scored from 1 "strongly disagree" to 4 "strongly agree", total scores range from 12 to 48 with a higher scores indicating greater hope. The items in the scale can be further divided into three factors of hope a) temporality and future, b) positive readiness and expectancy, and c) interconnectedness. Factor scores range from 4 to 16.
Measured: Baseline, 2 months, 4 months
Change from baseline in the General Self-Efficacy Scale (GSES) at 2 and 4 months.
The GSES is a 10 item 4-point scale. The scale assesses a person's perceived self-efficacy-their belief that they can complete novel or difficult tasks or cope with diversity. Total scores range from 10 to 40 with higher scores indicating a greater level of self-efficacy.
Measured: Baseline, 2 months, 4 months
Change from baseline in the Non Death Revised Grief Experience Inventory (NDRGEI) at 2 and 4 months.
The NDRGEI is a 22 item scale scored on a 6-point Likert scale from slightly disagree to strongly agree. The scale measures the grief experiences of persons anticipating a loss through four domains a) existential concerns (scores range 6-36), b) depression (scores range from 6-36), c) tension and guilt (scores range from 3-18), and d) physical distress (scores range from 7-42). The scale also offers a total grief score by calculating the sum of the four domains. The range for the total score is 22-132; higher scores indicate more grief.
Measured: Baseline, 2 months, 4 months
Change from baseline in 3 item loneliness score at 2 and 4 months.
The Three-Item Loneliness Scale is an interviewer-administered questionnaire developed from the Revised University of California Los Angeles (UCLA) Loneliness Scale. Each question is rated on a 3-point scale: 1 = Hardly Ever; 2 = Some of the Time; 3 = Often. All items are summed to give a total score. Scores range from 3 to 9 (higher scores indicate more loneliness)
Measured: Baseline, 2 months, 4 months
Change from baseline in Multidimensional Scale of Perceived Social Support at 2 and 4 months.
The Multidimensional Scale of Perceived Social Support (MSPSS) is a brief research tool designed to measure perceptions of support from 3 sources: Family, Friends, and a Significant Other. The scale is comprised of a total of 12 items, with 4 items for each subscale. The total score is an average, calculated by summing all items (which could range from 12 to 84) and dividing by 12 (higher scores indicate more social support).
Measured: Baseline, 2 months, 4 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2020
- Study start3 Feb 2020
- Primary completion30 Jun 2021
- Study completion31 Oct 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for DementiaStudies of the same condition, open and under way.
- More trials run by University of AlbertaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 234 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Alberta
- Sponsor type
- University, hospital or other
- Collaborators
- Public Health Agency of Canada (PHAC)
- Responsible party
- Sponsor
- Investigators
- Wendy Duggleby, PhD, Principal investigator, University of AlbertaHannah O'Rourke, PhD, Principal investigator, University of Alberta
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04226872
- Sponsor's protocol ID
- Pro00090771
- Status last verified
- Sep 2022
- First submitted
- 9 Jan 2020
- Last updated
- 2 Feb 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Duggleby W, Jovel Ruiz K, Ploeg J, McAiney C, Peacock S, Nekolaichuk C, Holroyd-Leduc J, Ghosh S, Brazil K, Swindle J, Forbes D, Woodhead Lyons S, Parmar J, Kaasalainen S, Cottrell L, Paragg J. Mixed-methods single-arm repeated measures study evaluating the feasibility of a web-based intervention to support family carers of persons with dementia in long-term care facilities. Pilot Feasibility Stud. 2018 Oct 31;4:165. doi: 10.1186/s40814-018-0356-7. eCollection 2018.
PubMed 30410783Duggleby W, O'Rourke H, Swindle J, Peacock S, McAiney C, Baxter P, Thompson G, Dube V, Nekolaichuk C, Ghosh S, Holroyd-Leduc J. Study protocol: pragmatic randomized control trial of my tools 4 care- in care (MT4C-in care) a web-based tool for family Carers of persons with dementia residing in long term care. BMC Geriatr. 2020 Aug 10;20(1):285. doi: 10.1186/s12877-020-01690-w.
PubMed 32778059
Study at a glance
From the registry record, last updated by the sponsor on 2 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Supporting Family Caregivers of Persons Living With Dementia: Effectiveness and Sustainability of My Tools 4 Care-In Care
- ClinicalTrials.gov ID
- NCT04226872
- Acronym / sponsor ID
- Pro00090771
- Keywords
- Caregivers, Quality of life, Dementia, Web-based intervention
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 234 participants (actual)
- Lead sponsor
- University of AlbertaUniversity, hospital or other
- Collaborators
- Public Health Agency of Canada (PHAC)
- Study start
- 3 Feb 2020 (actual)
- Primary completion
- 30 Jun 2021 (actual)
- Study completion
- 31 Oct 2021 (actual)
- First posted
- 13 Jan 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
When a person living with dementia moves into a long term care facility, their family members remain involved in their care. They learn new roles and make significant and often stressful adjustments. These caregivers are an at-risk group, and evidence suggests that their mental health may actually worsen after the person they are caring for moves into long term care. The research team previously created a free, web-based, interactive, intervention called My Tools 4 Care-In Care (MT4C-In Care) and tested it with 37 caregivers in Alberta. Caregivers found the toolkit to be easy to use, feasible, acceptable, and satisfactory, and reported increased hope and decreased loss and grief, after using it. Additionally, they reported that the toolkit helped them through the transitions they experience when their family member lives in long term care.
In this next study we want to see if MT4C-In Care can improve the quality of life, hope, social support, self-efficacy, and decrease the loss, grief and loneliness of family caregivers. During phase 1 the existing MT4C-In Care toolkit was reviewed with input from family caregivers of persons living with dementia in long term care through focus group interviews. The toolkit is now being revised and will be tested, during phase 2, with 280 caregivers of persons living with dementia in long term care across 4 provinces in Canada (Alberta, Ontario, Saskatchewan, and Manitoba). These caregivers will be randomly assigned into an intervention (caregivers with access to MT4C-In Care) and a control group (no access to MT4C-In Care).
Detailed description
Background: Caregivers of Persons Living with Dementia (PLWD) in a Long Term Care (LTC) community are an at-risk group, and evidence suggests that the caregiver's mental health may actually worsen after the PLWD moves to LTC. Caregivers may report feelings of blame, self-doubt, loneliness, isolation, and powerlessness which negatively affect their mental health. This at-risk group requires support to maintain and improve their quality of life. My Tools 4 Care - In Care (MT4C-In Care) is a self-administered, multicomponent, flexible, and interactive website designed specifically to support family caregivers of PLWD in LTC to address this gap in service and the significant concerns about their mental health. The feasibility study in Alberta demonstrated that MT4C-In Care is informative, convenient, and easy to use; and shows potential to help caregivers cope with the transitions and adjustments beyond the PLWD's admission to LTC, increasing caregivers' hope and decreasing their loss and grief.
Purpose: The purpose of Phase 2 is to implement and evaluate MT4C-In Care to assess its effectiveness, and the influence of participant factors (i.e., gender, cultural background, age, etc.) on the use of MT4C-In Care across four Canadian provinces (Alberta, Saskatchewan, Manitoba, and Ontario). The ability of MT4C-In Care to improve hope, self-efficacy, quality of life, social support, and mental health, and decrease grief and loneliness will be rigorously assessed in a pragmatic effectiveness trial with a large sample. The rigorous pragmatic trial, with in-depth mixed methods, will demonstrate whether MT4C-In Care works across four Canadian provinces as well as the reasons and mechanisms underlying its effects. MT4C-In Care will be updated based on pragmatic trial results in Jan-Feb 2022.
Participants: Total of approximately 280 participants from four provinces will be recruited (100 each from Alberta and Ontario and 40 each from Saskatchewan and Manitoba). Each province will hire a recruitment specialist, and Alzheimer Societies and other community partners within each province will support recruitment of participants by including information in newsletters, distributing brochures, and/or attending support group meetings, etc. Recruited participants will be randomly assigned to the intervention and control group (140 participants each group) via a centralized web-based randomization service (REDCap).
Data Collection: Trained research assistants in each province will 1) track all participants' participation throughout the study, 2) conduct surveys with all participants by phone to assess whether or not the intervention was effective in improving outcomes over time, as compared to the control group, and 3) conduct in-depth telephone interview with five to fifteen participants (depending on the province; see below).
Number of Participants in Surveys and In-depth Interviews: Alberta and Ontario: surveys with all 100 participants and in-depth interviews with 15 participants; Saskatchewan and Manitoba: surveys with all 40 participants and in-depth interview with 5 participants.
Outcome Data Collection: Immediately before and after the intervention, outcome and process data will be collected from all caregivers.There will be 3 Data Collection Points: Baseline before the start of the intervention; 2-month follow up immediately post-intervention; 4 month follow up after the end of the intervention.
Data Analysis: Outcome will be analyzed (using Generalized Estimating Equations) to assess whether MT4C-In Care is effective in the intervention as compared to the control group over time. We anticipate that the intervention group will experience improved hope, mental health, quality of life, social support, and self-efficacy, and less loneliness and grief, as compared to the control group. 140 participants in each of the intervention and control groups will allow for rigorous testing of these hypotheses.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Behavioral: My Tools for Care - In CareThe intervention group will receive access to My Tools for Care - In Care for 2 months. They will also receive a copy of the Alzheimer Society's "The Progression Of Alzheimer's Disease - Overview Booklet". |
| Control | No intervention | –The control group will not receive the intervention (i.e. they will not access My Tools for Care - In Care). They will receive a copy of the Alzheimer Society's "The Progression Of Alzheimer's Disease - Overview Booklet". Data collection for outcome variables will be the same as participants in the intervention group. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Family caregivers (≥18 years of age) of a person ≥65 years of age who has dementia that lives in a long-term care home
- English-speaking
- Has a valid email address and access to a computer and internet.
Key exclusion criteria (5 listed)
- Family caregivers of a person under the age of 65, who does not have dementia, or who does not reside in a long-term care home
- Care partner has died
- Non-English speaking
- Under 18 years of age
- No internet access or valid email
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| My Tools for Care - In CareSelf-administered web-based transition toolkit (My tools 4 Care - In Care) contains interactive activities and resources to help carers through transitions that they face after the person living with dementia has moved to a long-term care setting. | Behavioural | Intervention |
Primary outcome
Change from baseline in the 12-item Short-Form Health Survey (SF-12v2) - Mental Component Summary Score at two and four months
Time frame: Baseline, 2 months, 4 months
The SF-12v2 is a measure of health related quality of life and provides 2 scores 1) Mental Component Summary Score (MCS) and 2) Physical Component Summary Score (PCS). MCS scores range from 0 to 100, higher scores indicate better mental health related quality of life
6 secondary outcomes
Change from baseline in the 12-item Short-Form Health Survey (SF-12v2) - Physical Component Summary Score at 2 and 4 months.
Time frame: Baseline, 2 months, 4 months
Change from baseline in the Herth Hope Index Score (HHI) at 2 and 4 months.
Time frame: Baseline, 2 months, 4 months
Change from baseline in the General Self-Efficacy Scale (GSES) at 2 and 4 months.
Time frame: Baseline, 2 months, 4 months
Change from baseline in the Non Death Revised Grief Experience Inventory (NDRGEI) at 2 and 4 months.
Time frame: Baseline, 2 months, 4 months
Change from baseline in 3 item loneliness score at 2 and 4 months.
Time frame: Baseline, 2 months, 4 months
Change from baseline in Multidimensional Scale of Perceived Social Support at 2 and 4 months.
Time frame: Baseline, 2 months, 4 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Feb 2023.
- Background: PubMed 30410783Duggleby W, Jovel Ruiz K, Ploeg J, McAiney C, Peacock S, Nekolaichuk C, Holroyd-Leduc J, Ghosh S, Brazil K, Swindle J, Forbes D, Woodhead Lyons S, Parmar J, Kaasalainen S, Cottrell L, Paragg J. Mixed-methods single-arm repeated measures study evaluating the feasibility of a web-based intervention to support family carers of persons with dementia in long-term care facilities. Pilot Feasibility Stud. 2018 Oct 31;4:165. doi: 10.1186/s40814-018-0356-7. eCollection 2018.
- Derived from this study: PubMed 32778059Duggleby W, O'Rourke H, Swindle J, Peacock S, McAiney C, Baxter P, Thompson G, Dube V, Nekolaichuk C, Ghosh S, Holroyd-Leduc J. Study protocol: pragmatic randomized control trial of my tools 4 care- in care (MT4C-in care) a web-based tool for family Carers of persons with dementia residing in long term care. BMC Geriatr. 2020 Aug 10;20(1):285. doi: 10.1186/s12877-020-01690-w.
- Individual participant dataSharing planned: No
Related trials for Dementia
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
Not yet recruitingPhase 2
Lisdexamfetamine For the Treatment of Conduct Disorder in Children
Conduct Disorder
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Wendy Duggleby, PhD principal investigator
University of Alberta
Hannah O'Rourke, PhD principal investigator
University of Alberta
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing My Tools for Care - In Care in people with Dementia and Family, run by University of Alberta at 4 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in the 12-item Short-Form Health Survey (SF-12v2) - Mental Component Summary Score at two and four months (time frame: Baseline, 2 months, 4 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04226872, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2023.